Red Light Holland to Head Sponsor Psy-Fi Festival in The Netherlands from September 14-18, 2022, One Of The Largest Psy-Trance Festivals In Europe

Red Light Holland to Head Sponsor Psy-Fi Festival in The Netherlands from September 14-18, 2022, One Of The Largest Psy-Trance Festivals In Europe

  • Red Light Holland will be the exclusive provider of natural Psilocybin products at the festival estimated to host approximately 15,000 people
  • Red Light Holland will proudly sell their iMicrodose and Maka products and feature their technology Wisdom VR and Wisdom Truffle at Psy-Fi
  • Red Light Holland will provide educational workshops to promote the responsible use of Psychedelics

Toronto, Ontario–(Newsfile Corp. – July 13, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce its sponsorship of Psy-Fi festival, one of the largest international festivals in the Netherlands which attracts thousands of visitors each year. Psy-Fi offers a large variety of music, arts, and space for personal growth.

As a lead sponsor, Red Light Holland will be the exclusive provider of Psilocybin Truffles for the festival, including featuring the Company’s iMicrodose and Maka Brands. As part of the offerings to the festival, Red Light Holland will deploy its suite of technology products including the VR experience, Wisdom, which explains how Psychedelics influence the brain (https://store.steampowered.com/app/1561720/Wisdom/). Red Light Holland will also showcase their innovative meditation device, designed by world famous structural designer Karim Rashid, The Wisdom Truffle (www.WisdomTruffle.com). Red Light Holland will further provide preparation and integration workshops to promote the responsible use of Psychedelics. These efforts will be led by Jeff Hamburg, Red Light Holland’s therapist and expert psychedelic guide and Sarah Hashkes Red Light Holland’s Chief Innovation and Technology Officer. The Psy-Fi festival will take place in The Netherlands, September 14th-18th, 2022.

“This is a huge opportunity for us to connect to a worldwide audience that shares the same values of increasing legal access to naturally occuring Psilocybin. We are thrilled to collaborate with such a well-known and respected festival that is known for its safety-first practices as well as its care about the environment,” said Todd Shapiro, CEO, and Director of Red Light Holland. “We’re excited to show the world our Rec & Tech approach with our branded psilocybin products, technology devices and our educational and responsible use messaging aiming to bring people a lot of joy and connection.”

“Psy-Fi ‘Guardians of the Gala’ is set up to be one of the bigger Psy-Trance festivals in Europe. Our team is very pleased to be able to be such a big part of a beautiful and fun festival,” said Hans Derix, Red Light Holland’s President and Dutch Native. “We will be displaying and selling our Maka and iMicrodose products via our wholly owned company SR-Wholesale to thousands of people affordably and responsibly. And our intention is to have a big Brand presence. You should come down to our amazing country in September and check it out,” added Derix.

To learn more about the festival or purchase tickets go to: https://www.psy-fi.nl/.

Red Light Holland releases Data on Psychedelic Concert

Red Light Holland releases a report with data analysis around the success of the Company’s Psychedelic concert event on April 16th, 2022. During this event participants chose to consume between 1 to 8 grams of Red Light Holland’s premium Psilocybin truffles after an intake discussion with therapist and expert psychedelic guide Jeff Hamburg. After the event participants were sent a survey and the facilitators were interviewed for the report. A small number of participants replied, but with positive results.

  • 91.7% of the attendees in the survey reported they would be interested in attending another event, 75% reported they enjoyed the music more than usual
  • 41.7% reported they felt connected to the group in a meaningful way
  • 33.3% reported lasting benefits beyond the event itself

The long-term benefits included the release of negative emotions and a lasting “Uplifted mood”. Some participants also gained insight that helped them in their personal or professional life. No significant negative effects were reported or observed.

The report with detailed statistical analysis conducted by statistician Yoav Blonder, has been sent to Oregon Health Authority representatives and members of the Washington Psilocybin service workgroup, as well as other government officials around the world Red Light Holland is connected with, to help promote regulations and best practices for group psilocybin services.

While there is no statistical significance due to the small sample size Red Light Holland sees the potential of these events in increasing affordable and equitable accessibility, especially for newcomers to the psychedelic community, as newcomers might be more interested in trying psychedelics in a safe environment supervised by experts.

The Company can not make medical claims regarding the use of psilocybin.

To read the full report: https://redlight.co/wp-content/uploads/2022/07/Psychedelic-Concert-Report.pdf.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website:www.RedLight.co

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the details of the planned psy-fi festival September 14-18, 2022; the ability to sell Maka and iMicrodose products at the Psy-Fi Festival; comments with respect to the data discovered assisting Red Light if and when the final regulations in Oregon are approved; details with respect to Measure 109; Red Light’s plans to conduct further research in the Netherlands, statements regarding Red Light’s involvement in Psy-fi festival; the intended outcomes and effects of Measure 109; statements regarding the implementation of Measure 109 by the Oregon Health Authority; details regarding the sponsorship organzied by Red Light Holland including the ability to be the lead supplier of Red Light products at Psy-Fi Festival; Red Light’s expectations of obtaining the consent of concert-goers and participants to collect and analyze data on best practices on using psychedelics and the company’s products; Red Light’s plans to be the exclusive provider of Psilocybin Truffles for the festival and the company’s ability to deploy its suite of technology products including the VR experience, Wisdom and the company’s mediation device, The Wisdom Truffle; Red Light Holland; Red Light Holland premium psilocybin truffles being available for concert goers at the event; that sponsoring the event will enable Red Light to advocate for a program that helps a wide range of Oregonians; that the data provided from the past group microdosing event will illustrate a working model to help the Oregon Psilocybin Advisory Board and the Oregon Health Authority to refine psilocybin regulations as well as help form the Washington’s Psilocybin Wellness Workgroup; the belief that the report on microdosing services can benefit people or the inability for the report to represent medical claims; the company can not make medical claims; that the report and small sample size of the data will influence Oregon, Washington State Authorities to help with regulations; that the report is a small sample size and therefore is just a small sample of participants and not used for the purposes of medical advice.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: Red Light’s ability to carry the sponsorship and be the exclusive provider of Psilocybin Truffles for the festival; Red Light Holland setting up and deploying its suite of technology products including the VR experience, Wisdom and their innovative meditation device, The Wisdom Truffle. Red Light Holland will further provide preparation and integration workshops to promote the responsible use of Psychedelics discussed in this news release, or at all; the ability of the past group microdosing event and the subsequent report to yield the expected information to assist Red Light with legalization efforts described in this new release, or at all; the report will not affect the Measure 109 being implemented; Red Light Holland’s ability to continue as a going concern; the continued commercial viability and growth in popularity of psilocybin products; continued approval of Red Light Holland by the relevant governmental and/or regulatory authorities; the continued growth of Red Light Holland; details regarding the event organized by Psy-Fi Festival organizers, including the live performances; Red Light’s continued expectations of obtaining the consent of facilitators, concert organizers and participants including concert goers to provide psilocybin truffles; Red Light Holland premium products of psilocybin truffles being available for concert-goers at the event; that the report on the group microdosing event will illustrate a working model to help the Oregon Psilocybin Advisory Board and the Oregon Health Authority to refine psilocybin regulations as well as help form the Washington’s Psilocybin Wellness Workgroup; the inability of the report to be received, read by, or acknowledged by Oregon Authorities, Washington State Authorities and other Government agencies and officials around the world.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of Red Light to carry the sponsorship of Psy-Fi festival on the terms and timelines described in this news release; the potential inability of Red Light Holland to continue as a going concern; the risks associated with the psychedelics industry in general; increased competition in the recreational and medical psilocybin markets; the potential future unviability of the psychedelics industry; public opinion and perception of the psychedelics industry; incorrect assessment of the value and potential benefits of expansion plans and various transactions; risks associated with potential governmental and/or regulatory action with respect to the psychedelics industry; changes in general economic, business and political conditions, including changes in the financial and stock markets; and risks related to infectious diseases, including the impacts of the COVID-19 pandemic; the event not proceeding as detailed and no longer organized by Psy-Fi festival organizers, including the cancellation of all the performances at the festival and/or the planned and concurrently ability to offer of the company’s products during the event Sept 14-18 2022; the risk that Covid-19 could result in the canceling of the Psy-Fi festival, Red Light’s inability to sell products and promote best practices on usage of the company’s products; Red Light’s inability to sell products and promote best practices on usage of the company’s products at the Psy-Fi festival; Red Light Holland premium iMicrodose and Maka psilocybin truffles being unavailable for concert goers; that the report on the group microdosing event will not illustrate a working model to help the Oregon Psilocybin Advisory Board and the Oregon Health Authority to refine psilocybin regulations as well as not helping form the Washington’s Psilocybin Wellness Workgroup; the belief that the statistics provided on the microdosing event can become integrated into people’s daily life not come into fruition; the report does not represent a medical diagnosis; the report represents a very small sample size and does not represent any statistical significance.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect Red Light Holland’s expectations as of the date hereof and are subject to change thereafter. Red Light Holland undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

Nova Mentis to Present Promising
Psilocybin Microdose Data
at 18th NFXF International Fragile X Conference

Vancouver, British Columbia – July 11, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) during a poster presentation at the 18th NFXF International Fragile X Conference, taking place July 14–17, 2022 in San Diego, California.

Dr. Marvin S. Hausman, the Chairman of NOVA’s Scientific Advisory Board, will deliver a presentation titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome. NOVA’s recent research results showed that a very low microdose formulation of the Company’s proprietary psilocybin drug (NM-1001) significantly modulated behavioural and cognitive defects, in a genetic model of FXS.

Poster Presentation Details:

Presentation Title: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome
Date: Friday, July 15, 2022
Poster Reception Time: 4:30 pm – 6:30 pm

A video of NOVA’s presentation will be made available on the NFXF event app during the conference and the Company’s website following the event.

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).

Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.
For further information on the Company, please visit www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

The Trip of a Lifetime

DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A

Mark your calendar – DOSED 2: The Trip of a Lifetime is coming to the Vogue Theatre in Vancouver on  August 3rd! 

If you haven’t seen the original DOSED, check it out here. The award-winning documentary follows a woman overcoming opioid addiction with psilocybin and iboga.

DOSED 2 shares the remarkable story of a terminally-ill cancer patient who was granted the right to try psilocybin mushrooms to treat her end of life anxiety.

The special event premiere screening will be followed by an audience Q&A with:

  • Renowned addiction expert and author Dr. Gabor Maté
  • Legendary psychonaut Dennis McKenna
  • Psychedelic therapist (and your fave Daily Mushroom Podcast guest) Dave Phillips
  • Patient Laurie Brooks
  • Filmmakers Tyler Chandler & Nicholas Meyers
  • And more!

Get screening tickets

Watch the DOSED 2 trailer

Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

VANCOUVER, BC, July 6, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2022, after market close on Thursday, July 14, 2022.

Interested parties are invited to participate in the Company’s Q3 2022 results conference call and webcast occurring on the same day, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time. During the call, Numinus executives will review the Company’s performance and recent initiatives, and answer questions from analysts.

To listen to the live webcast, please register at: https://event.on24.com/wcc/r/3825889/3D9B9AD399CFA2D70257C91AC4C8F78A 

The webcast will also be archived on the Events and Presentations page of Numinus’ Investor Relations website: https://www.investors.numinus.com/events-and-presentations

To participate in the live conference call, please use the following dial-in information:

  • 1 (888) 330-3632 (Toll-free North America)
  • 1 (646) 960-0837 (International)
  • Please ask to participate in Numinus’ Q3 2022 Results Call. To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on July 14, 2022, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until July 28, 2022.About Numinus

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. 

Learn more at numinus.com and follow us on LinkedInFacebookTwitter, and Instagram.Forward-Looking Statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event “may”, “will”, “should”, “could” or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

SOURCE Numinus Wellness Inc.

For further information: Investor Contact: Jamie Kokoska, Vice President, Investor Relations & Communications, jamie.kokoska@numinus.com; Media Contact: May Lee, Communications Manager, may.lee@numinus.com

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

Calgary, AB – TheNewswire – June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO ) , ( OTC:IBOGF ) and ( FSE:JC4) (“ UI ” or the “ Company ”) a life sciences company with a mission to transform addiction treatment using medicalized ibogaine and a global licensing model is pleased to announce that Nick Karos, CEO will present at the H.C. Wainwright 1 st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond.  The event is a hybrid online and in person event scheduled for June 27, 2022.

About H.C. Wainwright

H.C. Wainwright & Co is one of the oldest and most trusted names in corporate finance in the USA providing investment banking, corporate advisory, research, and analysis covering sectors including Healthcare & Life Sciences, Mining, Cleantech, Shipping & Maritime and Technology.

H.C. Wainwright hosts a robust calendar of conferences and events in the Healthcare sector.  More information and registration for the 1 st Annual Mental Health Conference can be found here .

Nick Karos CEO of Universal Ibogaine commented “H.C. Wainwright is a leader in the space and could be a strong strategic partner in our ongoing corporate finance roadmap.  The opportunity to tell our story to this audience is another important step in developing the awareness around brand and offering.

Correction Notice June 13 Blue Digital Media

In UI’s June 13, 2022 News Release it was stated that stock options to be granted to investor relations advisory firm Blue Digital Media would vest one-third at the end of each month in the 3 month term of service. Under TSXV Exchange Policy 4.4 Security Based Compensation, stock options for investor relations firms must vest quarterly over a 12 month period with the first vesting for 25% of the options at 3 months,25% at 6 months, 25% at 9 months and the final 25% at 12 months.

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:  

Investor Relations: Dugan Selkirk, Investor Relations Manager 

dugan.selkirk@universalibogaine.com 

Related Links  https://universalibogaine.com

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

TORONTO, ONTARIO June 24, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from June 27 – 28, 2022 in New York.

Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address – Introduction to the State of Mental Healthcare – to kick off the conference on Monday, June 27 at 8:15 a.m. ET

Dr. McIntyre, will also deliver a second presentation on Monday, June 27 at 4:00 p.m. ET providing an overview of the Braxia’s business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression, while also expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors.

Braxia’s trials include Canada’s first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and recently reported positive preliminary results.

Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright and Co.

About Braxia Scientific Corp. 

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD

“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT:

Braxia Scientific Corp.

Tel: 416-762-2138

Email: info@braxiascientific.com

Website: www.braxiascientific.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release. 

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond, as follows:

Date:Monday, June 27, 2022
Time:10:30 a.m. ET
Location:The Lotte New York Palace Hotel

Investors participating in the conference who would like to schedule a one-on-one meeting with Pasithea’s CEO may do so by contacting their H.C. Wainwright representative or registering HERE.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Primary Logo

Source: Pasithea

Released June 23, 2022

BetterLife To Participate at the H.C. Wainwright 1st Annual
Mental Health Conference

BetterLife To Participate at the H.C. Wainwright 1st Annual
Mental Health Conference

June 23, 2022 08:00 ET | Source: BetterLife Pharma Inc.

  • VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that Dr. Ahmad Doroudian, Chief Executive Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 1st Annual Mental Health Conference being held on June 27th, 2022 in New York City, NY.

The theme of the conference is “Neuropsychiatry, Psychedelics, and Beyond.” The fireside chat will focus on the background of BetterLife and what differentiates it in the mental healthcare space.

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

For further information, please visit BetterLife Pharma.

Contact Information

David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

Matt Stang, CEO and Co-Founder of Delic Corp, will discuss the company’s strategic outlook for the remainder of the year and the latest developments at the nation’s largest ketamine provider, Ketamine Wellness Centers (KWC)

VANCOUVER, BRITISH COLUMBIA, June 23, 2022 – Delic Holdings Corp (“Delic” or the “Company”) (CSEDELC) (OTCQBDELCF) (FRA6X0), a leader in new medicines and treatments for a modern world, confirmed details regarding Delic Corp CEO Matt Stang’s virtual attendance at the first annual H.C. Wainwright Mental Health Conference on June 27, 2022.

H.C. Wainwright Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

June 27, 2022

Held at the Lotte New York Palace Hotel, the inaugural event will feature a full day of company presentations, networking opportunities and one-on-one investor meetings with a focus on neuropsychiatry, psychedelic and more. During this year’s conference, Stang will deliver a presentation that highlights the company’s strategic outlook for the remainder of the year and how the company is well-positioned to address the current mental health crisis. Stang will also discuss Ketamine Wellness Centers’ long-term growth strategy as the nation’s largest ketamine provider and the company’s latest patient programs such as the first-of-its-kind Veterans Administration (VA) partnership with the KWC Arizona clinics and the addition of SPRAVATO® and NAD+. His presentation will be available on June 27 starting at 7 a.m. ET. For more information regarding the first-ever H.C. Wainwright Mental Health Conference, please visit https://hcwevents.com/psychedelics/.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The Company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward-looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Investor Relations Contact
Rich Rodriguez
rich@deliccorp.com

Media Relations Contact
Clare Redlick
MATTIO Communications
clare@mattio.com 

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside chat at the H.C. Wainwright 1st Annual Mental Healthcare Conference taking place June 27, 2022.

Date: June 27, 2022
Time: 4:30 p.m. E.T.
Location: New York City

The fireside chat will be webcast live at 4:30 p.m. Eastern Time on Monday, June 27, through the following link: https://journey.ct.events/view/9a92c93f-2f82-4814-8d6a-22033c171e41. The webcast recording will also be accessible on Field Trip’s investor relations website and via the above link for 90 days.

Institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at fieldtripIR@kcsa.com.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centres for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information  

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including those set forth in the Company’s Annual Information Form and other market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

Investor contacts:
Kathleen Heaney / Sophia Bashford
KCSA Strategic Communications
fieldtripIR@kcsa.com

SOURCE Field Trip Health Ltd.